LLY is trading at $1,057.59 (+3.6%) as the FDA pledges swift action against illegal copycat weight-loss drugs, reversing yesterday's sharp 8% decline.
- The company recently reported Q4 revenue of $19.3B (43% YoY growth) and issued strong 2026 revenue guidance of $80-83B.
- Mounjaro and Zepbound drove results with $7.4B and $4.2B in Q4 sales, respectively, cementing Lilly's 60.5% market share in the obesity and diabetes drug sector.
- Investors remain optimistic ahead of a Medicare coverage expansion in July, which is expected to bolster growth despite ongoing pricing headwinds.